

Bacterin International Holdings, Inc.  
Form 8-K  
September 11, 2012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): September 11, 2012

Bacterin International Holdings, Inc.  
(Exact Name of Registrant as Specified in Its Charter)

Delaware  
(State or Other Jurisdiction of Incorporation)

001-34951                                  20-5313323  
(Commission File Number)              (IRS Employer Identification No.)

600 Cruiser Lane                                  59714  
Belgrade, Montana                              (Zip Code)  
(Address of Principal Executive Offices)

(406) 388-0480  
(Registrant's Telephone Number, Including Area Code)

Edgar Filing: Bacterin International Holdings, Inc. - Form 8-K

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

The Company has issued a press release entitled “Positive Clinical Results on the use of Bacterin’s OsteoSponge® SC Product for Regeneration of Subchondral Bone Published in *Foot & Ankle Specialist*” which is attached as Exhibit 99.1 and incorporated herein.

The information in this Item 7.01 and the document attached as Exhibit 99.1 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit No	Description
99.1	Press Release of Bacterin International Holdings, Inc. dated September 11, 2012 entitled “Positive Clinical Results on the use of Bacterin’s OsteoSponge® SC Product for Regeneration of Subchondral Bone Published in <i>Foot &amp; Ankle Specialist</i> ”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 11, 2012 **BACTERIN INTERNATIONAL HOLDINGS, INC.**

By: /s/ Guy S. Cook

Name: Guy S. Cook

Title: President and Chief Executive Officer

**EXHIBIT INDEX**

Press Release of Bacterin International Holdings, Inc. dated September 11, 2012 entitled “Positive Clinical  
99.1 Results on the use of Bacterin’s OsteoSponge® SC Product for Regeneration of Subchondral Bone Published in  
*Foot & Ankle Specialist*”